Adherence to the main prognosis-modifying drugs and the control of risk factors for coronary artery disease in patients after coronary stenting

Abstract

BACKGROUND: Adherence to drug therapy in patients with coronary artery disease is quite low nowadays, both in patients with myocardial infarction and in patients with chronic forms of coronary artery disease.

AIMS: of our work was to assess adherence to drug therapy (aspirin and statins) and control of risk factors for coronary artery disease in patients undergoing coronary stenting 12 months after endovascular treatment.

MATERIALS AND METHODS: The study included 279 patients, of whom 3 groups were formed. Patients of group 1 (n=96) personally visited the National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, adherence to the prescribed therapy and its effectiveness were assessed during the examination by a cardiologist, and if necessary, it was corrected. Patients of group 2 (n=95) contacted the study coordinator remotely. Patients of group 3 (n=88) were monitored by a general practitioner and visited a cardiologist at the National Medical Research Center of Cardiology according to the decision of the general practitioner.

RESULTS: At baseline, adherence to therapy in all groups was low and did not differ significantly between groups. 12 months after stenting, groups 1 and 2 showed a significant increase in the number of highly adherent individuals (from 17 to 33 and from 13 to 42, respectively, p <0.05), as well as a significant decrease in the number of individuals with low adherence to treatment (from 63 to 42 and from 67 to 36, respectively, p <0.05). The adherence to antiplatelet drugs was higher than to statins: 57.9% of people reduced the dose or stopped taking statins. After the follow-up time, there was a significant decrease in systolic blood pressure in groups 1 and 2 and a significant decrease in diastolic blood pressure in group 2. In group 2, a significant decrease in the number of smokers was noted: from 46.3 to 31.6% of the total number of patients in the group (p <0.05).

CONCLUSION: Active monitoring of patients by a cardiologist both during the visit and remotely contributes to an increase in adherence to drug therapy and improves control of risk factors for coronary artery disease.

Keywords

medication adherence / coronary artery disease / endovascular procedure

References

[1] Skopets IS, Vesikova NN, Marusenko IM, Malygin AN. Acute coronary syndrome: a comprehensive view of the problem, the importance of hospital and outpatient stages of treatment of patients. Archive Int Med. 2012;(3):58–64. (In Russ). doi: 10.20514/2226-6704-2012-0-3-58-64

[2] Скопец И.С., Везикова Н.Н., Марусенко И.М., Малыгин А.Н. Острый коронарный синдром: комплексный взгляд на проблему, значение госпитального и амбулаторного этапов лечения пациентов // Архивъ внутренней медицины. 2012. № 3. С. 58–64. doi: 10.20514/2226-6704-2012-0-3-58-64

[3] Hussain S, Jamal SZ, Qadir F. Medication adherence in post myocardial infarction patients. J Ayub Med Coll Abbottabad JAMC. 2018;30(4):552–557.

[4] Hussain S., Jamal S.Z., Qadir F. Medication adherence in post myocardial infarction patients // J Ayub Med Coll Abbottabad JAMC. 2018. Vol. 30, N 4. Р. 552–557.

[5] Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–3035. doi: 10.1161/CIRCULATIONAHA.108.768986

[6] Ho P.M., Bryson C.L., Rumsfeld J.S. Medication adherence: its importance in cardiovascular outcomes // Circulation. 2009. Vol. 119, N 23. Р. 3028–3035. doi: 10.1161/CIRCULATIONAHA.108.768986

[7] Puchinyan NF, Dovgalevsky YP, Dolotovskaya PV, Furman NV. Adherence to recommended therapy in patients who have undergone acute coronary syndrome and the risk of developing cardiovascular complications within a year after hospitalization. Rational Pharmacotherapy Cardiol. 2011;7(5):567–573. (In Russ).

[8] Пучиньян Н.Ф., Довгалевский Я.П., Долотовская П.В., Фурман Н.В. Приверженность рекомендованной терапии больных, перенесших острый коронарный синдром, и риск развития сердечно-сосудистых осложнений в течение года после госпитализации // Рациональная фармакотерапия в кардиологии. 2011. Т. 7, № 5. С. 567–573.

[9] Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107–1116. doi: 10.1001/jama.289.9.1107

[10] Gurwitz J.H., Field T.S., Harrold L.R., et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting // JAMA. 2003. Vol. 289, N 9. Р. 1107–1116. doi: 10.1001/jama.289.9.1107

[11] Maleva OV. Adherence to therapy of patients with coronary heart disease depending on the level of cognitive status. In: XXI Annual session of the A.N. Bakulev National Research Center with the All-Russian Conference of Young Scientists. Moscow; 2017. (In Russ).

[12] Малева О.В. Приверженность к терапии пациентов с ишемической болезнью сердца в зависимости от уровня когнитивного статуса // XXI Ежегодная сессия НЦССХ им. А.Н. Бакулева с Всероссийской конференцией молодых ученых, 21–23 мая. Москва, 2017.

[13] Soboleva MS. Factors of adherence to therapy of cardiovascular diseases according to modern research data. Clinician. 2017;11(2):33–39. (In Russ). doi: 10.17650/1818-8338-2017-11-2-33-39

[14] Соболева М.С. Факторы приверженности к терапии сердечно-сосудистых заболеваний по данным современных исследований // Клиницист. 2017. Т. 11, № 2. С. 33–39. doi: 10.17650/1818-8338-2017-11-2-33-39

[15] Sokolova NY. Adherence to therapy in patients with stable coronary artery disease after various revascularization procedures. Cardiology Vascular and Cardiac Surgery. 2019;12(1):25. doi: 10.17116/kardio20191201125

[16] Sokolova N.Yu. Adherence to therapy in patients with stable coronary artery disease after various revascularization procedures // Cardiology Vascular and Cardiac Surgery. 2019. Vol. 12, N 1. Р. 25. doi: 10.17116/kardio20191201125

[17] Biryukova LA. Adherence to the treatment of patients with ischemic heart disease with pain and pain-free form. Siberian Medical Journal (Irkutsk). 2008;79(4):75–77. (In Russ).

[18] Бирюкова Л.А. Приверженность к лечению больных ишемической болезнью сердца с болевой и безболевой формой // Сибирский медицинский журнал (Иркутск). 2008. Т. 79, № 4. С. 75–77.

[19] Naumova EA, Semenova ON. Modern view on the problem of patients’ adherence to long-term treatment. Cardiology: News Opinions Training. 2016;(2):30–39. (In Russ).

[20] Наумова Е.А., Семенова О.Н. Современный взгляд на проблему приверженности пациентов к длительному лечению // Кардиология: Новости. Мнения. Обучение. 2016. № 2. С. 30–39.

[21] Lukina YV, Kutishenko NP, Dmitrieva NA, Martsevich SY. Adherence of patients with chronic ischemic heart disease to medical recommendations (according to the outpatient registry profile). Russ J Cardiol. 2017;(3):14–19. (In Russ).

[22] Лукина Ю.В., Кутишенко Н.П., Дмитриева Н.А., Марцевич С.Ю. Приверженность больных хронической ишемической болезнью сердца к врачебным рекомендациям (по данным амбулаторного регистра профиль) // Российский кардиологический журнал. 2017. № 3. С. 14–19.

[23] Glezer MG; On Behalf Of The Choice-Study Participants OBOTC-SP. Treatment of patients with stable ischemic heart disease in real clinical practice in Russia. The CHOICE-2 program. Kardiologiia. 2016;56(5):5–11. (In Russ).

[24] Glezer M.G.; On Behalf Of The Choice-Study Participants OBOTC-SP. Treatment of patients with stable ischemic heart disease in real clinical practice in Russia. The CHOICE-2 program. (In Russian) // Kardiologiia. 2016. Vol. 56, N 5. Р. 5–11.

[25] Lee HY, Cooke CE, Robertson TA. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm JMCP. 2008;14(3):271–280. doi: 10.18553/jmcp.2008.14.3.271

[26] Lee H.Y., Cooke C.E., Robertson T.A. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge // J Manag Care Pharm JMCP. 2008. Vol. 14, N 3. Р. 271–280. doi: 10.18553/jmcp.2008.14.3.271

[27] Lukina YV, Kutishenko NP, Martsevich SY. Adherence to treatment: a modern view of a familiar problem. Cardiovascul Therapy Prevent. 2017;16(1):91–95. doi: 10.15829/1728-8800-2017-1-91-95

[28] Лукина Ю.В., Кутишенко Н.П., Марцевич С.Ю. Приверженность лечению: современный взгляд на знакомую проблему // Кардиоваскулярная терапия и профилактика. 2017. Т. 16, № 1. С. 91–95. doi: 10.15829/1728-8800-2017-1-91-95

[29] Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497. doi: 10.1056/NEJMra050100

[30] Osterberg L., Blaschke T. Adherence to medication // N Engl J Med. 2005. Vol. 353, N 5. Р. 487–497. doi: 10.1056/NEJMra050100

[31] Kuzheleva EA, Borel KN, Garganeeva AA. Low adherence to treatment after myocardial infarction: causes and methods of correction taking into account the psychoemotional state of patients. Ration Pharmacother Cardiol. 2016;12(3):291–295. doi: 10.20996/1819-6446-2016-12-3-291-295

[32] Кужелева Е.А., Борель К.Н., Гарганеева А.А. Низкая приверженность лечению после перенесенного инфаркта миокарда: причины и способы коррекции с учетом психоэмоционального состояния пациентов // Рациональная фармакотерапия в кардиологии. 2016. Т. 12, № 3. С. 291–295. doi: 10.20996/1819-6446-2016-12-3-291-295

[33] Mathews R, Peterson ED, Honeycutt E, et al. Early medication nonadherence after acute myocardial infarction: insights into actionable opportunities from the TReatment with ADP receptor iNhibitorS: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study. Circ Cardiovasc Qual Outcomes. 2015;8(4):347–356. doi: 10.1161/CIRCOUTCOMES.114.001223

[34] Mathews R., Peterson E.D., Honeycutt E., et al. Early medication nonadherence after acute myocardial infarction: insights into actionable opportunities from the TReatment with ADP receptor iNhibitorS: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study // Circ Cardiovasc Qual Outcomes. 2015. Vol. 8, N 4. Р. 347–356. doi: 10.1161/CIRCOUTCOMES.114.001223

[35] Faridi KF, Peterson ED, McCoy LA, et al. Timing of first postdischarge follow-up and medication adherence after acute myocardial infarction. JAMA Cardiol. 2016;1(2):147–155. doi: 10.1001/jamacardio.2016.0001

[36] Faridi K.F., Peterson E.D., McCoy L.A., et al. Timing of first postdischarge follow-up and medication adherence after acute myocardial infarction // JAMA Cardiol. 2016. Vol. 1, N 2. Р. 147–155. doi: 10.1001/jamacardio.2016.0001

[37] Davidovich IM, Malai LN, Kutishenko NP. Long-term results and adherence to therapy in patients after acute myocardial infarction: registry data (Khabarovsk). Clinician. 2017;11(1):36–44. (In Russ). doi: 10.17650/1818-8338-2016-10-4-36-44

[38] Давидович И.М., Малай Л.Н., Кутишенко Н.П. Отдаленные результаты и приверженность терапии у пациентов после острого инфаркта миокарда: данные регистра (Хабаровск) // Клиницист. 2017. Т. 11, № 1. С. 36–44. doi: 10.17650/1818-8338-2016-10-4-36-44

[39] Ergatoudes C, Thunström E, Rosengren A, et al. Long-term secondary prevention of acute myocardial infarction (SEPAT) ― guidelines adherence and outcome. BMC Cardiovasc Disord. 2016;16(1):226. doi: 10.1186/s12872-016-0400-6

[40] Ergatoudes C., Thunström E., Rosengren A., et al. Long-term secondary prevention of acute myocardial infarction (SEPAT) ― guidelines adherence and outcome // BMC Cardiovasc Disord. 2016. Vol. 16, N 1. Р. 226. doi: 10.1186/s12872-016-0400-6

[41] Lopatina VE. Adherence to treatment in patients with coronary heart disease. Scientific Research. 2016;2(3):54–57. (In Russ).

[42] Лопатина В.Е. Приверженность лечению у пациентов с ишемической болезнью сердца // Научные исследования. 2016. Т. 2, № 3. С. 54–57.

RIGHTS & PERMISSIONS

Osokina A.K., Shchinova A.M., Potekhina A.V., Filatova A.Y., Sorokin E.V., Dolgusheva Y.A., Efremova Y.E., Lazareva N.V., Gornyakova N.В., Barabanova E.A., Provatorov S.I.